Fida Biosystems ApS. (3/13/24). "Press Release: In-Solution Kinetics by Fida Biosystems – Redefining Drug Interaction Analysis for Therapeutic Discovery". Copenhagen.

	Organisation	Fida Biosytems ApS
	Product	Fida Neo System
	Product 2	Flow Induced Dispersion Analysis technology (FIDA technology)
	Person	Sørensen, Brian (Fida Biosystems 202403 CEO)

Fida Biosystems today announced a significant expansion to the capabilities of its proprietary Flow Induced Dispersion Analysis (FIDA) technology with the integration of in-solution kinetics. This enhancement comes with a launch of Fida Neo – the new generation of Fida Instrument, and builds upon FIDA's established proficiency in affinity and quality assessments, reinforcing the technology's position at the forefront of biomolecular research. The latest advancement enables the direct determination of kon and koff in drug-target interactions within their native environments, devoid of the biases introduced by traditional immobilisation techniques.

Brian Sørensen, CEO of Fida Biosystems, stated, "The inclusion of in-solution kinetics into FIDA's analytical repertoire marks a pivotal evolution in our technology. This capability allows for a high-fidelity representation of biomolecular behaviors, facilitating earlier identification of the optimal therapeutic candidates and potentially reducing the cost of subsequent clinical trials."

The traditional assessment of drug-target interactions has relied on immobilising one of the binding partners, often leading to non-specific binding and the need for laborious surface regeneration. Building on Taylor Dispersion Analysis in a microscale capillary system, FIDA offers a new direct-measurement based approach, which precisely controls reaction times via the manipulation of sample introduction in the capillary. This first-principle, immobilisation free method to in-solution analysis negates the environmental restrictions that have historically constrained biomolecular studies, such as buffer composition, temperature, and ionic strength.

With the FIDA 1 system already established as a robust tool for measuring affinity, quality, and quantity, the integration of in-solution kinetics further solidifies FIDA's role in the market as the most comprehensive solution for biophysics research across pharmaceutical, biotech, and academic sectors.

For more information on the impact of FIDA's in-solution kinetics on biomolecular interaction studies and therapeutic development, contact Brian Sørensen ([email protected]) or visit fidabio.com.

About Fida Biosystems:

Fida Biosystems is the proprietary developer of Flow Induced Dispersion Analysis technology, specializing in the first-principle analysis of biomolecular interactions. Committed to scientific accuracy and methodological efficiency, Fida Biosystems continues to innovate in response to the complex demands of drug discovery and development research area.

Record changed: 2024-03-14

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

» top